Samsung Pharm (001360) - Total Liabilities

Latest as of September 2025: ₩44.04 Billion KRW ≈ $29.85 Million USD

Based on the latest financial reports, Samsung Pharm (001360) has total liabilities worth ₩44.04 Billion KRW (≈ $29.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Samsung Pharm - Total Liabilities Trend (2012–2024)

This chart illustrates how Samsung Pharm's total liabilities have evolved over time, based on quarterly financial data. See Samsung Pharm working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Samsung Pharm Competitors by Total Liabilities

The table below lists competitors of Samsung Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
LINMON MEDIA LTD -000025 F:8MN	Germany	€832.79 Million
Stars Microelectronics (Thailand) PCL BK:SMT	Thailand	฿676.62 Million
Bundamedik Tbk PT JK:BMHS	Indonesia	Rp1.62 Trillion
Michael Hill International Ltd AU:MHJ	Australia	AU$374.48 Million
RF Acquisition Corp II Ordinary Shares NASDAQ:RFAI	USA	$5.19 Million
Fast Ejendom CO:FED	Denmark	Dkr924.33 Million
Vaziva Sa PA:ALVAZ	France	€10.65 Million
Mevaco S.A AT:MEVA	Greece	€26.61 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Samsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Samsung Pharm worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.54	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samsung Pharm (2012–2024)

The table below shows the annual total liabilities of Samsung Pharm from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩22.60 Billion ≈ $15.31 Million	+42.17%
2023-12-31	₩15.89 Billion ≈ $10.77 Million	+3.72%
2022-12-31	₩15.32 Billion ≈ $10.39 Million	-15.73%
2021-12-31	₩18.19 Billion ≈ $12.32 Million	-67.99%
2020-12-31	₩56.81 Billion ≈ $38.50 Million	+121.03%
2019-12-31	₩25.70 Billion ≈ $17.42 Million	-11.32%
2018-12-31	₩28.98 Billion ≈ $19.64 Million	-51.95%
2017-12-31	₩60.33 Billion ≈ $40.88 Million	+7.90%
2016-12-31	₩55.91 Billion ≈ $37.89 Million	-33.43%
2015-12-31	₩83.98 Billion ≈ $56.91 Million	+146.17%
2014-12-31	₩34.12 Billion ≈ $23.12 Million	-50.05%
2012-12-31	₩68.31 Billion ≈ $46.29 Million	--

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$91.21 Million

₩134.59 Billion KRW

Market Cap Rank

#19656 Global

#1008 in Korea

Share Price

₩1430.00

Change (1 day)

+3.92%

52-Week Range

₩1302.00 - ₩2210.00

All Time High

₩12289.83